• Completed

NCT00473590: Phase 2 - Bevacizumab in Combination With Bortezomib in MM (AMBER)

Updated: Jun 15

NCT00473590: Phase 2: A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) (AMBER)


avastin myeloma

This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.


Sponsor

Genentech, Inc.

 

ClinicalTrials.gov Identifier: NCT00473590

Official Title: A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : May 15, 2007


Click here for details on ClinicalTrials.gov

 

Drug: Bevacizumab

Drug: Bortezomib

Drug: placebo

 

Definition of bortezomib - NCI Drug Dictionary - National Cancer Institute

Bevacizumab : MedlinePlus Drug Information

 

Cancer; 2013

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

Click here for details





220 views
Posts Archive